Cargando…
r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction
Vascular endothelial growth factor (VEGF) is critical for physiological and pathological angiogenesis. Within the tumor microenvironment, VEGF functions as an endothelial cell survival factor, permeability factor, mitogen, and chemotactic agent. The majority of these functions are mediated by VEGF-i...
Autores principales: | Sullivan, Laura A., Carbon, Juliet G., Roland, Christina L., Toombs, Jason E., Nyquist-Andersen, Mari, Kavlie, Anita, Schlunegger, Kyle, Richardson, James A., Brekken, Rolf A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917360/ https://www.ncbi.nlm.nih.gov/pubmed/20700512 http://dx.doi.org/10.1371/journal.pone.0012031 |
Ejemplares similares
-
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
por: Dineen, Sean P, et al.
Publicado: (2008) -
Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
por: Roland, Christina L., et al.
Publicado: (2009) -
Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation
por: Arnold, Shanna A., et al.
Publicado: (2012) -
VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer
por: Lynn, Kristi D., et al.
Publicado: (2010) -
Molecular and Clinical Aspects of Targeting the VEGF Pathway in Tumors
por: Korpanty, Grzegorz, et al.
Publicado: (2010)